Do you have salivary or pancreatic cancer եք Offer licensed therapy for bladder cancer. While the approach may seem surprising at first glance, it is becoming more and more common for some oncology patient management. A French study presented at the World Congress of Cancer by the American Society of Clinical Oncology (ASCO) provides new arguments in favor of a “pan-oncology” approach.
Ragnar’s trial evaluated the target therapy, erdafitinib, for treating more than twenty different types of cancer. This molecule is available in France for the treatment of some metastatic and / or inoperable bladder cancers. “This treatment focuses on the molecular features that are present in the fusion of certain urothelial cancers, mutations or FGFR 2 և 3 genes. However, these abnormalities have been found in about twenty different tumor types with varying frequency. ” explain…
Source: Le Figaro
